Equities

Harrow Inc

HROW:NMQ

Harrow Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.47
  • Today's Change1.14 / 2.51%
  • Shares traded1.00
  • 1 Year change+217.85%
  • Beta0.7454
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Harrow Inc have a median target of 45.00, with a high estimate of 50.00 and a low estimate of 44.80. The median estimate represents a -3.16% decrease from the last price of 46.47.
High7.6%50.00
Med-3.2%45.00
Low-3.6%44.80

Earnings history & estimates in USD

On Aug 07, 2024, Harrow Inc reported 2nd quarter 2024 losses of -0.18 per share. This result exceeded the -0.21 consensus loss of the 4 analysts covering the company and under-performed last year's 2nd quarter results by 28.57%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate-21.13%
Harrow Inc reported annual 2023 losses of -0.74 per share on Mar 19, 2024.
Average growth rate-149.93%
More ▼

Revenue history & estimates in USD

Harrow Health, Inc. had 2nd quarter 2024 revenues of 48.94m. This bettered the 42.51m consensus of the 4 analysts covering the company. This was 87.48% above the prior year's 2nd quarter results.
Average growth rate+11.28%
Harrow Health, Inc. had revenues for the full year 2023 of 130.19m. This was 46.95% above the prior year's results.
Average growth rate+28.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.